EPO: Appeal Board vetoes EPC regulation
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

EPO: Appeal Board vetoes EPC regulation

Veto final

In the latest international briefing for the EPO, Jakob Pade Frederiksen looks at the law around the patenting of plant and animal varieties as well as biological processes for the production of plants and animals

Following the so-called Tomato II and Broccoli II decisions rendered by the EPO's Enlarged Board of Appeal (EBA) in 2015, the politically delicate question of patentability of plant or animal varieties as well as essentially biological processes for the production of plants or animals has once again occupied the EPO, now with the uncomfortable implication that a Technical Board of Appeal of the EPO has revealed a conflict between two legal provisions within the framework of the EPC.

The Tomato II and Broccoli II decisions, G 2/12 and G 2/13, held that products derived from essentially biological processes may be patentable, even if the process used to obtain the product is essentially biological and hence not patentable. In particular, the EBA concluded that Article 53(b) EPC, excluding plant or animal varieties and essentially biological processes for the production of plants or animals from patentability, did not extend to plants or plant material or plant parts other than a plant variety.

In the wake of these decisions, the European Commission released a notice in November 2016 stating that the EU legislator's intention when adopting the Biotech Directive (98/44/EC) was to exclude from patentability plants, animals and parts thereof obtained by means of essentially biological processes. Against this background, the Administrative Council of the EPO implemented as of July 1 2017 new Rule 28(2) EPC specifying that under Article 53(b) EPC, "European patents shall not be granted in respect of plants or animals exclusively obtained by means of an essentially biological process."

According to decision T 1063/18 concerning the refusal under Rule 28(2) EPC of EP 2 753 168, made available on February 5 2019, a Technical Board of Appeal of the EPO held that Rule 28(2) EPC is in conflict with Article 53(b) EPC, as interpreted by the EBA in the above-referred decisions. In accordance with Article 164(2) EPC, the Appeal Board held that the provisions of the convention, i.e. Article 53(b) EPC shall prevail. In other words, Rule 28(2) is null and void.

Given the public interest in the matter concerned and the ethical aspects involved, and having regard to political signals from relevant EU bodies, it seems likely that further legislative initiatives may soon be taken in order to resolve the conflict between EU legislators' views and the provisions of Article 53(b) EPC.

frederiksen.jpg

Jakob Pade Frederiksen

Inspicos P/S

Kogle Allé 2

DK-2970 Hoersholm

Copenhagen, Denmark

Tel: +45 7070 2422

Fax: +45 7070 2423

info@inspicos.com

www.inspicos.com

more from across site and ros bottom lb

More from across our site

The former head of life sciences at Kramer Levin has joined Orrick, a firm that hopes to grow in the sector
Lionel Martin of August Debouzy and Kristof Neefs at Inteo share how they prevailed in a UPC Court of Appeal case surrounding access to documents
Counsel say ‘strange’ results have increased their reliance on subscription-based search platforms, but costs are not being shifted onto clients yet
The firm was among multiple winners at a record-breaking 2024 ceremony held in London on April 11
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
The Americas research cycle has commenced. Do not miss this opportunity to nominate your work!
Increased and new patent fees could affect prosecution strategies for law firms and companies, according to sources
Five former Oblon lawyers felt that joining Merchant & Gould would help them offer the right prices to entice clients
The UK may not be a UPC member but its firms are still acting in proceedings, with Carpmaels among the most prominent
Naomi Pearce of Pearce IP shares how she is helping her firm become a life sciences leader and how generous policies have helped attract top talent
Gift this article